JP2017516870A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516870A5
JP2017516870A5 JP2017516633A JP2017516633A JP2017516870A5 JP 2017516870 A5 JP2017516870 A5 JP 2017516870A5 JP 2017516633 A JP2017516633 A JP 2017516633A JP 2017516633 A JP2017516633 A JP 2017516633A JP 2017516870 A5 JP2017516870 A5 JP 2017516870A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
subject
antigen
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017516633A
Other languages
English (en)
Japanese (ja)
Other versions
JP6686007B2 (ja
JP2017516870A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2015/050651 external-priority patent/WO2015187087A2/en
Publication of JP2017516870A publication Critical patent/JP2017516870A/ja
Publication of JP2017516870A5 publication Critical patent/JP2017516870A5/ja
Application granted granted Critical
Publication of JP6686007B2 publication Critical patent/JP6686007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017516633A 2014-06-04 2015-06-04 抗原ベース療法薬の新規な併用 Active JP6686007B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1450678-6 2014-06-04
SE1450678 2014-06-04
SE1451315-4 2014-11-04
SE1451315 2014-11-04
PCT/SE2015/050651 WO2015187087A2 (en) 2014-06-04 2015-06-04 Novel combinations for antigen based therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020066176A Division JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Publications (3)

Publication Number Publication Date
JP2017516870A JP2017516870A (ja) 2017-06-22
JP2017516870A5 true JP2017516870A5 (https=) 2018-06-28
JP6686007B2 JP6686007B2 (ja) 2020-04-22

Family

ID=54767532

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017516633A Active JP6686007B2 (ja) 2014-06-04 2015-06-04 抗原ベース療法薬の新規な併用
JP2020066176A Pending JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020066176A Pending JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Country Status (20)

Country Link
US (3) US20170196949A1 (https=)
EP (2) EP3760224A3 (https=)
JP (2) JP6686007B2 (https=)
CN (2) CN106535926B (https=)
AU (3) AU2015268960B2 (https=)
CA (2) CA2950893C (https=)
CY (1) CY1123160T1 (https=)
DK (1) DK3151853T3 (https=)
ES (1) ES2807787T3 (https=)
HU (1) HUE051151T2 (https=)
IL (3) IL300130B2 (https=)
LT (1) LT3151853T (https=)
PL (1) PL3151853T3 (https=)
PT (1) PT3151853T (https=)
RS (1) RS60581B1 (https=)
RU (1) RU2702632C2 (https=)
SI (1) SI3151853T1 (https=)
SM (1) SMT202000384T1 (https=)
WO (1) WO2015187087A2 (https=)
ZA (1) ZA202204777B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
IL273016B2 (en) * 2017-09-08 2024-10-01 Diamyd Medical Ab Genotype stratification in diabetes treatment and prevention
EP4300102A3 (en) 2017-09-08 2024-01-24 Diamyd Medical AB Improved immunotherapy
WO2019151939A1 (en) * 2018-02-05 2019-08-08 Diamyd Medical Ab Novel composition and use thereof
US11752156B2 (en) 2018-03-07 2023-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders
US10500217B2 (en) 2018-04-30 2019-12-10 Leslie Ray Matthews, M.D., Llc Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
EP3952859A4 (en) * 2019-04-12 2023-05-10 Loma Linda University METHODS OF TREATMENT OF NIEMANN-PICK DISEASE TYPE C
WO2022104388A2 (en) * 2020-11-16 2022-05-19 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled injection devices without fatty acid particles
US20240245762A1 (en) * 2021-01-13 2024-07-25 University Of Maryland, College Park Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
US20240277768A1 (en) * 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells
WO2023066881A1 (en) * 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
EP0869815A1 (en) * 1995-09-21 1998-10-14 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
US6884785B2 (en) 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
EP2322185A3 (en) * 2001-11-21 2011-08-10 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
US20050152914A1 (en) * 2003-06-13 2005-07-14 Diamyd, Inc. Formulation of antigen
WO2005076965A2 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
EP1755631A2 (en) * 2004-03-03 2007-02-28 Diamyd Medical AB Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
JP2009511014A (ja) * 2005-10-05 2009-03-19 ベイヒル セラピューティクス インコーポレーティッド 自己免疫疾患の処置のための組成物および方法
CN101646781B (zh) * 2006-12-29 2016-06-22 科罗拉多大学董事会 自身免疫病的诊断和治疗靶标及其用途
AU2008222678B2 (en) * 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
US20090092637A1 (en) * 2007-04-24 2009-04-09 Diamyd Therapeutics Ab Medicaments and methods to treat autoimmune disease and cancer
EP2630966B1 (en) * 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
CN101945666A (zh) * 2007-12-19 2011-01-12 Mivac发展股份公司 治疗自身免疫和过敏性疾病的组合物及方法
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012062697A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2017516870A5 (https=)
RU2016150656A (ru) Новые комбинации для антигенной терапии
Xie et al. Enteroendocrine hormone secretion and metabolic control: importance of the region of the gut stimulation
Li et al. L-Theanine improves immunity by altering TH2/TH1 cytokine balance, brain neurotransmitters, and expression of phospholipase C in rat hearts
Ferretti et al. Adaptive immune regulation in autoimmune diabetes
Colceriu-Șimon et al. The effects of non-steroidal anti-inflammatory drugs used for orthodontic pain management on tooth movement: a comprehensive review of the literature
Riaz et al. PPARs at the crossroads of T cell differentiation and type 1 diabetes
Issazadeh-Navikas NKT cell self-reactivity: evolutionary master key of immune homeostasis?
Page et al. Adaptive responses in severe acute malnutrition: Endocrinology, Metabolomics, Mortality, and growth
Cook et al. Prospects of a type 1 diabetes vaccine
Juedes et al. Regulatory T‐cells in type 1 diabetes
US20200138920A1 (en) Novel Combinations for Antigen Based Therapy
Tian et al. Active Immunization with Glucose‐Dependent Insulinotropic Polypeptide Vaccine Influences Brain Function and Behaviour in Rats
HRP20201030T1 (hr) Dekarboksilaza glutaminske kiseline (gad) za uporabu za liječenje autoimune bolesti
Garren A DNA vaccine for multiple sclerosis
Fabbrini et al. Soluble and controlled-release preparations of levodopa: do we really need them?
Rajasalu et al. Experimental Autoimmune Diabetes: A New Tool to Study Mechanisms and Consequences of Insulin‐Specific Autoimmunity
JP2928608B2 (ja) インスリン依存型糖尿病予防または治療剤
CA3015577A1 (en) Agents for increasing the secretion of anti-inflammatory cytokines
RU2824503C2 (ru) Новые комбинации для антигенной терапии
Van et al. All-trans retinoic acids inhibits type 1 diabetes by Treg-dependent suppression of IFN-γ-producing-T-cells without affecting Th17 cells
Singh et al. Therapeutic Perspectives in Type-1 Diabetes
Sonino et al. Long-Acting Octreotide LAR Compared with Lanreotide SR in the Treatment of Acromegaly
Brugman et al. Neonatal oral administration of DiaPep277 combined with hydrolyzed casein diet protects against type 1 diabetes. An experimental study.